Japan Study Confirms: mRNA COVID Shots Linked to Aggressive ‘Turbo Cancers’
A groundbreaking study out of Japan has confirmed what many independent doctors and researchers have been warning since the rollout of COVID-19 mRNA injections: these shots are contributing to a dramatic rise in aggressive, fast-moving cancers—often called “turbo cancers.”
Published in PrePrints and led by Dr. Makoto Abue of the Miyagi Cancer Center, the study analyzed outcomes in 272 pancreatic cancer patients between 2018 and 2023. Researchers found that patients who received three or more doses of mRNA vaccines had significantly worse survival outcomes, with the average survival time cut in half—dropping from 20.8 months in unvaccinated patients to just 10.3 months in those who were vaccinated.
Using immune markers such as elevated IgG4 levels and increased infiltration of Foxp3+ T-regulatory cells (Tregs), the team found biological evidence that mRNA shots may be suppressing the immune system’s natural ability to fight tumors. A multivariate regression analysis showed that ≥3 vaccine doses was an independent predictor of worse outcomes—on par with late-stage disease and lack of surgery—with a hazard ratio of 4.08.
These findings come as growing numbers of oncologists and immunologists raise red flags about the potential long-term effects of the mRNA platform. U.S. FDA labs recently confirmed dangerous levels of DNA contamination in Pfizer’s mRNA product—up to 470 times the legal safety limit—raising further questions about mutagenic risk and immune dysfunction.
Renowned cancer surgeon Dr. Patrick Soon-Shiong also weighed in during a recent interview with Tucker Carlson, stating the spike protein itself may be triggering the rise in aggressive cancers: “It scares the pants off me,” he said, calling it a potential global health crisis.
The Japanese study authors are now calling for urgent further research into the immunological consequences of mRNA vaccination—particularly in cancer patients.
Originally published in Slay News
*********************************************************************************************************************